

## Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **December 1, 2021** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at [www.ab.bluecross.ca/dbl/publications.php](http://www.ab.bluecross.ca/dbl/publications.php).

Please refer to the December 1, 2021 updates for complete listings of products available by special authorization, added products, new established interchangeable groupings, Least Cost Alternative (LCA) price changes, products with a price change and discontinued products.

Please note that the online Interactive Drug Benefit List (iDBL) at [www.ab.bluecross.ca/dbl/idbl\\_main1.php](http://www.ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application, and as such, contains the most up-to-date information.

### Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Estradiol Derm 100 (8 mg/pth) Transdermal Patch (DIN 02246969) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 20, 2021**. The following grouping was removed from the Critical Supply Product List **November 19, 2021**.

#### ESTRADIOL-17B

##### 100 MCG/DAY TRANSDERMAL PATCH

00002246969	SANDOZ ESTRADIOL DERM 100 (8 MG/PTH)	SDZ	\$ 3.0181
00002244002	ESTRADOT 100 (1.56 MG/PTH)	NOV	\$ 3.5600

Alberta Blue Cross has been advised by Actavis Pharma Company that the shortage for Act Dextroamphetamine SR 15 mg Sustained-Release Capsule (DIN 02448327) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 20, 2021**. The following grouping was removed from the Critical Supply Product List **November 19, 2021**.

#### DEXTROAMPHETAMINE SULFATE

##### 15 MG SUSTAINED-RELEASE CAPSULE

00002448327	ACT DEXTROAMPHETAMINE SR	APH	\$ 0.9898
00001924567	DEXEDRINE	PAL	\$ 1.1510

continued next page

# PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Clindamycin/Benzoyl Peroxide 1%/5% Topical Gel (DIN 02440180) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 22, 2021**. The following grouping was removed from the Critical Supply Product List **November 22, 2021**.

## CLINDAMYCIN PHOSPHATE/ BENZOYL PEROXIDE

### 1 % / 5 % TOPICAL GEL

<b>00002440180</b>	<b>TARO-CLINDAMYCIN/BENZOYL PEROXIDE</b>	<b>TAR</b>	<b>\$ 0.6857</b>
00002243158	CLINDOXYL	GSK	\$ 0.9798

## Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Apo-Amitriptyline 10 mg Tablet (DIN 02403137) manufactured by Apotex Inc. and Elavil 10 mg Tablet (DIN 00335053) manufactured by AA Pharma Inc., pms-Amitriptyline 10 mg Tablet (DIN 00654523) and Mar-Amitriptyline 10 mg Tablet (DIN 02429861) will be considered temporary benefits for the *ADBL*. This grouping was added to the Critical Supply Product List **November 19, 2021**.

As of **November 18, 2021**, all claims for pms-Amitriptyline 10 mg Tablet (DIN 00654523) and Mar-Amitriptyline 10 mg Tablet (DIN 02429861) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

## Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Ene-Med Rectal Enema (NPN 02231170) manufactured by H.J. Sutton/Quality Home Products and Fleet Rectal Enema (NPN 00009911) manufactured by C.B. Fleet Company Inc, Lax-A Nema Rectal Enema (NPN 02096900), manufactured by Pendopharm Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

C.B. Fleet Company Inc has advised Alberta Blue Cross that the shortage of Fleet Rectal Enema (NPN 00009911) has been resolved.

As a result, Lax-A Nema Rectal Enema (NPN 02096900) will no longer be considered a temporary benefit for the *ADBL* after December 22, 2021. Lax-A Nema Rectal Enema (NPN 02096900) was removed from the Critical Supply Product List **November 23, 2021**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)  
403-294-4041 (Calgary and area)  
1-800-361-9632 (toll free)  
FAX 780-498-8406 (Edmonton and area)  
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](https://www.ab.bluecross.ca/providers/pharmacy-home.php)

